Abivax (NASDAQ:ABVX – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by equities research analysts at Citizens Jmp in a report released on Wednesday,Benzinga reports. They currently have a $187.00 target price on the stock. Citizens Jmp’s price target indicates a potential upside of 36.07% from the stock’s current price.
A number of other equities analysts have also recently issued reports on the stock. Wedbush boosted their price objective on shares of Abivax from $90.00 to $110.00 and gave the company a “neutral” rating in a research report on Tuesday. Truist Financial cut their target price on Abivax from $140.00 to $135.00 and set a “buy” rating on the stock in a research note on Tuesday, June 2nd. Wolfe Research set a $136.00 price target on Abivax in a report on Wednesday, June 3rd. Oddo Bhf reaffirmed an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Finally, Barclays increased their price objective on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Fourteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Abivax presently has an average rating of “Moderate Buy” and a consensus price target of $144.46.
View Our Latest Report on ABVX
Abivax Stock Up 3.1%
Abivax (NASDAQ:ABVX – Get Free Report) last posted its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million for the quarter, compared to the consensus estimate of $0.40 million. As a group, equities analysts predict that Abivax will post -3.4 EPS for the current fiscal year.
Hedge Funds Weigh In On Abivax
Several hedge funds and other institutional investors have recently modified their holdings of the stock. GHP Investment Advisors Inc. raised its stake in Abivax by 155.6% in the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after buying an additional 140 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after acquiring an additional 369 shares during the period. Bank of America Corp DE raised its position in shares of Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after acquiring an additional 1,990 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Abivax by 661.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after acquiring an additional 344 shares in the last quarter. Finally, WPG Advisers LLC lifted its stake in shares of Abivax by 125.9% in the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares during the period. Hedge funds and other institutional investors own 47.91% of the company’s stock.
Trending Headlines about Abivax
Here are the key news stories impacting Abivax this week:
- Positive Sentiment: Updated Phase 2/3 data for obefazimod showed meaningful clinical benefit in hard-to-treat ulcerative colitis patients and reinforced the maintenance safety database, easing earlier concerns about cancer signals. Article title
- Positive Sentiment: Reuters and other outlets highlighted that the drug showed benefit in relapsed and non-responding patients, supporting the view that the therapy could address a difficult-to-treat market. Article title
- Positive Sentiment: Several analysts turned more constructive, including Jefferies upgrading ABVX to buy and Leerink raising its price target, which can reinforce bullish sentiment after the data readout. Article title
- Neutral Sentiment: Abivax temporarily halted and then resumed trading in Paris while it finalized a large ADS offering, signaling a financing move rather than a change in the underlying drug data. Article title
- Negative Sentiment: The company launched and then upsized a large public offering of American Depositary Shares, which could dilute existing shareholders even as it strengthens the balance sheet. Article title
Abivax Company Profile
Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.
Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.
Read More
- Five stocks we like better than Abivax
- 3 Big Banks Plan Double Digit Dividend Increases After Passing Fed Stress Test
- 3 ETFs Offering Exposure to Latin America’s Stock Market Rally
- Could Apple’s China Play Be the Answer to Its Memory Pressure Problem?
- 3 Charts That Could Change the Course of Summer Trading
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
